Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-negative Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-negative Breast Cancer
Interventions: DRUG: pegylated liposomal doxorubicin hydrochloride|DRUG: epirubicin hydrochloride|DRUG: carboplatin|PROCEDURE: therapeutic conventional surgery|DRUG: paclitaxel|OTHER: laboratory biomarker analysis|OTHER: quality-of-life assessment
Sponsor: Rutgers, The State University of New Jersey
Collaborators: National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey